Article | June 21, 2022

Advances In Technology And Support For Direct-To-Patient (DTP) Services

By Leandro Moreira, SVP, Corporate Development, Yourway

DTP

The COVID-19 pandemic has led to widespread embrace across the industry of decentralized clinical trials models, including direct-to-patient (DTP) and direct-from-patient (DFP) supply and healthcare services. However, the pandemic has also introduced novel challenges and complications with DTP and DFP logistics.

A specific new challenge the industry is facing due to the implementation of DTP trials is quality-by-inspection instead of quality-by-design. Quality-by-inspection relies on identifying quality issues after they have occurred, while quality-by-design emphasizes product and process understanding, as well as control and a risk management approach to predict quality issues before they arise. Quality-by-inspection can hinder innovation because it requires constant change when something new arises.

The pandemic has also made patient enrollment a bigger challenge. Almost 85% of clinical trials fail to maintain viability because of inability to retain enough patients. Furthermore, patients who are immunocompromised have unique challenges since any travel at all may place them at unnecessary risk, especially during the pandemic. Virtual patient management, including DTP care, decentralization, and telemedicine have expanded the capabilities of ongoing trials.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online

Yourway, The Biopharma Services Company